Company news

Noxopharm Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4D and Half Year 2022 Financial Report

February 21, 2022

December 2021 Quarterly Activities Report and Appendix 4C

January 26, 2022

Noxopharm Receives A$5.865M R & D Tax Rebate

January 6, 2022

Noxopharm Announces Leadership Transition

January 4, 2022

Noxopharm DARRT-2 Cancer Trial Update

December 13, 2021

Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research

December 1, 2021

Licencing Deal Expands Noxopharm Drug Opportunities

November 16, 2021

Retraction of Grant Announcement

November 16, 2021

Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial

November 14, 2021

Noxopharm Announces DARRT-2 Clinical Trial in U.S.

November 9, 2021

Veyonda and Opdivo IONIC Study First Patient Dosed

October 25, 2021

Patent Granted for Veyonda and Low Dose Chemotherapy

October 25, 2021

September 2021 Quarterly Activities Report and Appendix 4C

October 13, 2021

Veyonda Achieves Important U.S. Patent Claims

September 27, 2021

Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

August 26, 2021

Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

August 25, 2021

Pre-clinical Data Supports a Role for Veyonda in COVID-19

August 23, 2021

NOXCOVID Program to Expand After Positive Phase 1 Results

August 22, 2021

Noxopharm: Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer

August 12, 2021

NOX and US Govt Peak Cancer Agency Announce Collaboration

August 8, 2021

Veyonda Survival Advantage in LuPSMA Therapy Confirmed

August 5, 2021

June 2021 Quarterly Activities Report and Appendix 4C

July 26, 2021

DARRT-2 Study Receives IND Approval from FDA

June 30, 2021

Noxopharm Secures Key European Patent Allowance for Veyonda

June 29, 2021

DARRT-2 Study Update and Clarification

June 9, 2021

Noxopharm Set to Benefit From Novartis ASCO Data

June 4, 2021

New Independent Trial Data Supports Potential of Veyonda

May 30, 2021

Veyonda to Begin First-Line Sarcoma Treatment Testing

May 11, 2021

Veyonda FDA Approved Trial to Commence

May 6, 2021

Publications Positive Review of Veyonda in Chemotherapy

April 29, 2021

Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm

April 27, 2021

March Quarterly Activities Report and Appendix 4C

April 26, 2021

Veyonda Showing Potential to Prevent Cytokine Storm

April 22, 2021

Noxopharm Files Septic Shock Treatment Patent for Veyonda®

April 14, 2021

Veyonda Patent Lodged for Major Septic Shock Opportunity

April 5, 2021

Noxopharm IONIC Immuno-Oncology Trial Commences

March 18, 2021

NOXCOVID Trial Advances to Final Stage

March 7, 2021

Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate

March 1, 2021

Company Announcement Regarding Appendix 3Y Disclosures

February 23, 2021

Appendix 4D and Half Year Financial Report

February 15, 2021

LuPIN Survival Outcome Confirmed by Conference Presentation

February 14, 2021

Major Survival Benefit in Prostate Cancer Patients Announced

February 8, 2021

Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C

January 24, 2021

NOXCOVID Study Advances

January 12, 2021

Pre-Clinical Breakthrough Discovery Set to Expand Pipeline

December 6, 2020

Noxopharm Completes A$23m Placement to Fund Clinical Studies

December 3, 2020

Independent Discovery Validates DARRT Cancer Therapy

November 12, 2020

Veyonda To Be Tested In Combination With Opdivo In Trial

November 8, 2020

Dedicated Septic Shock Company Established

November 5, 2020

Noxopharm Quarterly Activities Report & Appendix 4C

October 14, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 53 decks. Every deck is listed under its year.